)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lexeo Therapeutics
Lexeo Therapeutics (LXEO) investor relations material
Lexeo Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary29 Oct, 2026
Company overview and business model
Clinical-stage gene therapy portfolio targets genetic cardiovascular and neurological diseases, including Friedreich ataxia cardiomyopathy and PKP2-related arrhythmogenic cardiomyopathy.
LX2006 is in the enrolling SUNRISE-FA 2 pivotal study; LX2020 is in the Phase 1/2 HEROIC-PKP2 trial. Advanced programs use AAVrh10 vectors.
Strategy centers on treating underlying genetic causes in diseases with high unmet need; candidates use vectors, doses and administration routes selected for intended biodistribution and safety.
Use of proceeds and capital allocation
Proceeds’ intended use will be specified in each offering supplement; pending deployment, funds may be held in bank deposits, money market funds, Treasury obligations and investment-grade securities.
Broad discretion is retained over net proceeds from securities sales.
Risk factors and disclosures
Investment is described as high risk; investors are directed to offering-specific supplements and incorporated annual, quarterly and current reports for risk factors.
LX2006 safety update: generally well tolerated, no Grade 3 treatment-related SAEs or clinically significant complement activation; one possibly related Grade 2 asymptomatic myocarditis event was reported.
Forward-looking statements carry known and unknown risks; actual outcomes may differ materially, and securities may have no established trading market or limited liquidity.
Emerging growth and smaller reporting company status permits reduced disclosures; elected accounting-standard transition timing may complicate comparisons and affect trading activity or share-price volatility.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lexeo Therapeutics
- LX2020’s upcoming readout will focus on durable, clinically meaningful NSVT reduction.LXEO
Investor update - LX2006 milestones extend through 2028 as Q4 PKP2 data approach.LXEOChardan's 10th Annual Healthcare Conference
- Pivotal and phase I gene therapy programs advance with major data and regulatory milestones ahead.LXEO2026 Global Healthcare Conference
- Pivotal FA and PKP2 gene therapy programs advance with strong data, broad pipeline, and robust cash runway.LXEOStifel 2026 Virtual Cardiometabolic Forum
- Gene therapy programs advance with strong clinical data, scalable manufacturing, and commercial readiness.LXEO12th Annual Cantor Fitzgerald Global Healthcare Conference
- Acquisition expands the FA platform with multimodal therapies and $21.3M in payments.LXEOM&A announcement
- Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway.LXEOCorporate presentation
- LX2006 pivotal trial and LX2020 RMAT status drive progress; cash runway extends into 2028.LXEOQ2 2026
- LX1001 showed dose-dependent APOE2 expression, reduced tau, and no ARIA in APOE4 Alzheimer's.LXEOStudy Update
Next Lexeo Therapeutics earnings date
Q3 202612 Nov, 2026
Lexeo Therapeutics
Next Lexeo Therapeutics earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lexeo Therapeutics Inc. operates as a clinical-stage genetic medicine company focused on hereditary and acquired diseases. The company is advancing a portfolio of gene therapy candidates, including LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy, and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 mutations. Additionally, Lexeo Therapeutics is developing therapies for APOE4 homozygous conditions and CLN2 Batten disease, among others, utilizing its AAVrh10-based gene therapy platform. The company is headquartered in New York, New York, and its shares are listed on the Nasdaq.